CA3095331A1 - Cancer serum biomarkers and methods of use thereof - Google Patents

Cancer serum biomarkers and methods of use thereof Download PDF

Info

Publication number
CA3095331A1
CA3095331A1 CA3095331A CA3095331A CA3095331A1 CA 3095331 A1 CA3095331 A1 CA 3095331A1 CA 3095331 A CA3095331 A CA 3095331A CA 3095331 A CA3095331 A CA 3095331A CA 3095331 A1 CA3095331 A1 CA 3095331A1
Authority
CA
Canada
Prior art keywords
cancer
cytokine
patient
biomarker
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3095331A
Other languages
English (en)
French (fr)
Inventor
Yan Wang
Simon Paul Fricker
Kam Marie Sprott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
X4 Pharmaceuticals Inc
Original Assignee
X4 Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X4 Pharmaceuticals Inc filed Critical X4 Pharmaceuticals Inc
Publication of CA3095331A1 publication Critical patent/CA3095331A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
CA3095331A 2018-04-13 2019-04-12 Cancer serum biomarkers and methods of use thereof Pending CA3095331A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862657370P 2018-04-13 2018-04-13
US62/657,370 2018-04-13
US201862734133P 2018-09-20 2018-09-20
US62/734,133 2018-09-20
US201862756496P 2018-11-06 2018-11-06
US62/756,496 2018-11-06
PCT/US2019/027169 WO2019200223A1 (en) 2018-04-13 2019-04-12 Cancer serum biomarkers and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3095331A1 true CA3095331A1 (en) 2019-10-17

Family

ID=68164571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3095331A Pending CA3095331A1 (en) 2018-04-13 2019-04-12 Cancer serum biomarkers and methods of use thereof

Country Status (6)

Country Link
US (1) US20210025895A1 (https=)
EP (1) EP3775877A4 (https=)
JP (1) JP2021521439A (https=)
CN (1) CN112005114A (https=)
CA (1) CA3095331A1 (https=)
WO (1) WO2019200223A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CN112771177A (zh) * 2018-05-21 2021-05-07 纳米线科技公司 分子基因标签及其使用方法
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
WO2021263115A1 (en) * 2020-06-26 2021-12-30 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
US12523658B2 (en) * 2021-08-27 2026-01-13 The Board Of Regents Of The University Of Texas System Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications
CA3233049A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Lymphatic fluid for diagnostics
CN114859050B (zh) * 2022-05-30 2026-02-17 复旦大学附属肿瘤医院 三阴性乳腺癌免疫治疗疗效预测标志物ccl19的检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6483705B2 (en) * 2001-03-19 2002-11-19 Harris Corporation Electronic module including a cooling substrate and related methods
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
EP3230498B1 (en) * 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
WO2016168133A1 (en) * 2015-04-17 2016-10-20 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
CA3010617A1 (en) * 2016-01-22 2017-07-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11337969B2 (en) * 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
JP2021521439A (ja) 2021-08-26
EP3775877A4 (en) 2021-12-22
EP3775877A1 (en) 2021-02-17
WO2019200223A1 (en) 2019-10-17
CN112005114A (zh) 2020-11-27
US20210025895A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
US20210025895A1 (en) Cancer serum biomarkers and methods of use thereof
US11705220B2 (en) Systems and methods for identifying cancer treatments from normalized biomarker scores
Sun et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Prenen et al. Tumor-associated macrophages: a short compendium
US20210349099A1 (en) Cancer biomarkers and methods of use thereof
Nayak et al. Circulating immune cell and outcome analysis from the phase II study of PD-L1 blockade with durvalumab for newly diagnosed and recurrent glioblastoma
CN109153722A (zh) 用于治疗癌症的方法
CN115667552A (zh) 与对局部晚期或转移性尿路上皮癌中的免疫疗法敏感性相关的肿瘤突变负荷
Hays The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma
TW202603361A (zh) 胰臟癌患者之ｉｌ—６抑制劑與化學療法之併用療法之治療效果預測法
HK40017854A (en) Systems and methods for identifying cancer treatments from normalized biomarker scores
HK40017854B (en) Systems and methods for identifying cancer treatments from normalized biomarker scores